Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne B Hendrix

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Neurology. Clinical Practice|March 9, 2023
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study FindingsAlette M Wessels, Ellen B Dennehy, Sherie A Dowsett, et al.
The Lancet. Neurology|November 4, 2017
24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trialHilkka Soininen, Alina Solomon, Pieter Jelle Visser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 13, 2020
36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's diseaseHilkka Soininen, Alina Solomon, Pieter Jelle Visser, et al.
Frontiers in Medical Technology|July 6, 2026
Efficacy assessment in trials of complex and rare diseases: a comparison between the meta-analytic global statistical test and co-primary analysisSamuel P Dickson, Abe Durrant, Caleb W Dayley, et al.
The Journal of Prevention of Alzheimer'S Disease|October 27, 2025
The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trialsSamuel P Dickson, Craig Mallinckrodt, Aaron H Burstein, et al.
The Lancet. Neurology|May 3, 2008
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trialGordon K Wilcock, Sandra E Black, Suzanne B Hendrix, et al.
Alzheimer'S Research & Therapy|May 21, 2015
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysisAlireza Atri, Suzanne B Hendrix, Vojislav Pejović, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentSamuel P Dickson, Benjamin A Haaland, Kent Hendrix, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersGarrett B Duncan, Tyler M Duke, Samuel B Johnson, et al.
International Psychogeriatrics|March 19, 2025
Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer's disease: A factor analysisSuzanne B Hendrix, Mary Sano, Constantine Lyketsos, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Neurology. Clinical Practice|March 9, 2023
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study FindingsAlette M Wessels, Ellen B Dennehy, Sherie A Dowsett, et al.
The Lancet. Neurology|November 4, 2017
24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trialHilkka Soininen, Alina Solomon, Pieter Jelle Visser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 13, 2020
36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's diseaseHilkka Soininen, Alina Solomon, Pieter Jelle Visser, et al.
Frontiers in Medical Technology|July 6, 2026
Efficacy assessment in trials of complex and rare diseases: a comparison between the meta-analytic global statistical test and co-primary analysisSamuel P Dickson, Abe Durrant, Caleb W Dayley, et al.
The Journal of Prevention of Alzheimer'S Disease|October 27, 2025
The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trialsSamuel P Dickson, Craig Mallinckrodt, Aaron H Burstein, et al.
The Lancet. Neurology|May 3, 2008
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trialGordon K Wilcock, Sandra E Black, Suzanne B Hendrix, et al.
Alzheimer'S Research & Therapy|May 21, 2015
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysisAlireza Atri, Suzanne B Hendrix, Vojislav Pejović, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentSamuel P Dickson, Benjamin A Haaland, Kent Hendrix, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersGarrett B Duncan, Tyler M Duke, Samuel B Johnson, et al.
International Psychogeriatrics|March 19, 2025
Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer's disease: A factor analysisSuzanne B Hendrix, Mary Sano, Constantine Lyketsos, et al.
Pageof 4